Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
EMA Screener
SMA Screener
WMA Screener
OHLC Screener
Fibonacci Screener
VWAP Screener
Pivot Point Screener
Overlay Screener
Trend Indicator Screener
Volume Based Indicator Screener
Overbought/Sold Screener
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodayPrecious Metals
Gold Price TodayNew
Silver Price TodayNew
Platinum Price TodayNewSmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Lincoln Pharmaceuticals
Small Cap•1,687 Employees•IPO 1996
Current Price
₹734.15
2 (0.27%)Updated
Today's Range
731
₹734.15
750.2
52 Week Range
52W Low₹440.00
52W High₹735.00
₹734.15
Downside66.85%
Upside0.12%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹1,233.63 Cr
Market Cap
Total market value of companyP/E Ratio
14.05
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
1.49
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹43.86
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
4.55%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
17.30%
ROCE
Return on Capital Employed. >15% is goodNet Margin
13.47%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
9.83%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
10.03%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
4.61%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
16.90%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
-
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹335.34
Book Value
Net asset value per shareDividend Yield
0.29%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
49.80%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Zero debt significantly strengthens Lincoln's financial position, providing flexibility to pursue growth opportunities and withstand economic downturns without the burden of high interest payments. This is a major positive for investors.
- •The company's Price-to-Earnings (PE) ratio of 12.40 is lower than the sector PE of 13.19, suggesting it might be undervalued compared to its industry peers, offering potential for re-rating.
Weaknesses
4 points- •The stock has seen significant volatility, dropping from a 52-week high of ₹980 to a current price of ₹533, indicating potential market uncertainty and investor concerns about its stability.
- •While promoter holding is substantial at 49.8%, it is just below the 50% mark, which could raise minor concerns about absolute control and potential for future dilution or strategic shifts.
Opportunities
2 points- •The Pharmaceuticals sector is generally resilient and poised for growth due to increasing healthcare spending, an aging global population, and rising demand for generic drugs, offering a favorable market.
- •Expansion into new therapeutic areas or geographical markets could significantly boost revenue and market share, leveraging existing manufacturing capabilities and R&D expertise for diversification.
Threats
2 points- •Intense competition from larger, well-established pharmaceutical players like Sun Pharma and Divi's Lab could pressure pricing and market share, impacting Lincoln's growth trajectory and profitability.
- •Strict and evolving regulatory environments in the pharmaceutical industry, including drug approvals and manufacturing standards, pose compliance risks and could lead to increased operational costs.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹784.30 | +₹50.15 | +6.83% |
| R3 | ₹765.10 | +₹30.95 | +4.22% |
| R2 | ₹757.65 | +₹23.50 | +3.20% |
| R1 | ₹745.90 | +₹11.75 | +1.60% |
| PIVOT | ₹738.45 | 4.30 | 0.59% |
| CURRENT | ₹734.15 | - | - |
| S1 | ₹688.30 | -₹45.85 | -6.25% |
| S2 | ₹707.50 | -₹26.65 | -3.63% |
| S3 | ₹719.25 | -₹14.90 | -2.03% |
| S4 | ₹726.70 | -₹7.45 | -1.01% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-51.4% vs avg
1.39L
(22 May 2026)Delivery %-2.8% vs avg
40.5%
(22 May 2026)Avg Volume (20D)20-day average
2.86L
(24 Apr - 22 May)Avg Delivery %Trend ↓
43.3%
(24 Apr - 22 May)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Wanbury Ltd
1197.00 %
Highest Dividend Yield
Anuh Pharma Ltd
1.85 %
Peer Comparison
| Company Name |
|---|
 Amrutanjan Health Care Ltd |
 Anuh Pharma Ltd |
 Bajaj Healthcare Ltd |
 Beta Drugs Ltd |
 Indoco Remedies Ltd |
 Ind-Swift Laboratories Ltd |
 Jagsonpal Pharmaceuticals Ltd |
 NGL Fine Chem Ltd |
 Sakar Healthcare Ltd |
 Sigachi Industries Ltd |
 Sun Pharmaceutical Industries Ltd |
 Syncom Formulations (India) Ltd |
 Themis Medicare Ltd |
 TTK Healthcare Ltd |
 Venus Remedies Ltd |
 Wanbury Ltd |
About
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Limited is an Indian pharmaceutical company primarily involved in the manufacturing and trading of a wide range of pharmaceutical products within India and for export to approximately 60 countries globally. These countries span several continents, including Europe, Canada, Latin and North America, Africa, the Asia Pacific region, and Southeast Asia, demonstrating a significant international presence for the company.
Their product portfolio is extensive, covering various therapeutic areas. This includes common ailments like colds, as well as more specialized treatments for conditions such as ear, nose, and throat (ENT) issues, pain, gastrointestinal problems, malaria, fungal infections, and skin conditions. Beyond this, Lincoln Pharmaceuticals offers products addressing more serious health concerns, including diabetes, hypertension (high blood pressure), gynecological issues, cardiovascular diseases (cardio and CNS), respiratory problems, and dyslipidemia (high cholesterol).
A key aspect of their business model is the production and distribution of branded generics. This means they produce medications that are similar to brand-name drugs but are sold under their own brand name at typically lower prices. This strategy likely caters to both domestic and international markets where cost-effectiveness is a crucial factor in accessing essential medicines. The breadth of their therapeutic areas, coupled with their export-oriented approach, suggests a strategy aimed at capturing a significant share of both the domestic and international pharmaceutical markets.
Established in 1979 and headquartered in Ahmedabad, India, Lincoln Pharmaceuticals has a history spanning several decades in the pharmaceutical industry. Their longevity and continued expansion into international markets indicate successful navigation of the competitive landscape and a robust business strategy that effectively combines manufacturing capabilities with a well-defined global distribution network. The company's diversified product portfolio positions it to address a broad spectrum of healthcare needs across various geographic regions.
COMPANY FACTS - LINCOLN
Registered Address
LINCOLN HOUSE, B/h. Satyam Complex, Science City Road, Sola
Ahmedabad
GUJARAT
IN
Tel: 917967778000
Website:https://www.lincolnpharma.com/
Investor Relations:http://www.lincolnpharma.com/about-us/investors/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,687
IPO Date: 08/02/1996
MANAGEMENT - LINCOLN
Mr. Kishor Shah
Non-Executive Non-Independent Chairman of the Board
Mr. Darshit Shah
Chief Financial Officer
Ms. Trusha Shah
Compliance Officer, Company Secretary
Mr. Mahendrabhai Patel
Managing Director, Executive Director
Mr. Ashish Patel
Whole Time Director
Mr. Hasmukhbhai Patel
Whole Time Director
Mr. Munjal Patel
Whole Time Director
Mr. Rajnikant Patel
Non-Executive Non-Independent Director
Ms. Seema Mehta
Additional Non-Executive Woman Independent Director
Mr. Saurin Parikh
Non-Executive Independent Director
Mr. Nareshkumar Suthar
Additional Non-Executive Independent Director
Investor Questions Answered
Lincoln Pharmaceuticals Ltd (LINCOLN) Stock FAQs
Get answers to the most common questions about Lincoln Pharmaceuticals Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Lincoln Pharmaceuticals Ltd (LINCOLN) is ₹734.15. Today, the stock has gained by ₹2.00 (0.27%), trading in a range of ₹731 to ₹750.2. The stock opened at ₹736 with a trading volume of 1,38,940 shares.
Lincoln Pharmaceuticals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,233.63 crores, P/E ratio of 14.05, ROE of 4.55%, and ROCE of 17.30%. The dividend yield stands at 0.29%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Lincoln Pharmaceuticals Ltd (LINCOLN) is ₹735, while the 52-week low is ₹440. Currently trading at ₹734.15, the stock is 99.7% away from its 52-week low and 0.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Lincoln Pharmaceuticals Ltd stock at ₹734.15 depends on multiple factors. The stock is currently trading with a P/E ratio of 14.05 and P/B ratio of N/A. Today's performance shows a gain of 0.27%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Lincoln Pharmaceuticals Ltd offers a dividend yield of 0.29%, which means for every ₹100 invested at the current price of ₹734.15, you can expect to receive approximately ₹0.29 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Lincoln Pharmaceuticals Ltd's key financial metrics include: P/E Ratio: 14.05, P/B Ratio: N/A, ROE: 4.55%, ROCE: 17.30%, Dividend Yield: 0.29%, EPS: ₹43.86, Book Value: ₹335.34, Debt-to-Equity: 0.00, and Current Ratio: N/A. The company's market cap stands at ₹1,233.63 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Lincoln Pharmaceuticals Ltd stock opened at ₹736 and is currently trading at ₹734.15, showing a gain of ₹2.00 (0.27%). The intraday high is ₹750.2 and low is ₹731. The trading volume stands at 1,38,940 shares, indicating moderate market participation today.
Lincoln Pharmaceuticals Ltd has a Price-to-Earnings (P/E) ratio of 14.05, which means investors are willing to pay ₹14.05 for every ₹1 of earnings. With an EPS of ₹43.86, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Lincoln Pharmaceuticals Ltd has a market capitalization of ₹1,233.63 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹734.15) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Lincoln Pharmaceuticals Ltd has a book value of ₹335.34 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹734.15, which is 118.9% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Lincoln Pharmaceuticals Ltd has a Return on Equity (ROE) of 4.55% and Return on Capital Employed (ROCE) of 17.30%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Lincoln Pharmaceuticals Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Lincoln Pharmaceuticals Ltd has a debt-to-equity ratio of 0.00, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Lincoln Pharmaceuticals Ltd has an Earnings Per Share (EPS) of ₹43.86, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹734.15 and P/E ratio of 14.05, investors are paying 14.05 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Lincoln Pharmaceuticals Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Lincoln Pharmaceuticals Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Lincoln Pharmaceuticals Ltd stock, consider: 1) Fundamental Analysis - Review P/E (14.05), ROE (4.55%), debt-to-equity (0.00), and growth rates. 2) Technical Analysis - Check 52-week range (₹440.00 - ₹735.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹734.15) with book value (₹335.34) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Lincoln Pharmaceuticals Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹734.15 is 7241x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Lincoln Pharmaceuticals Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹440.00 - ₹735.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.00 indicates leverage. 4) Liquidity Risk - Based on trading volume of 1,38,940 shares. 5) Valuation Risk - P/E of 14.05 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Lincoln Pharmaceuticals Ltd operates in the industry with key metrics: P/E ratio of 14.05, ROE of 4.55%, market cap of ₹1,233.63 crores, and dividend yield of 0.29%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.00), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Lincoln Pharmaceuticals Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹734.15, with a 52-week range of ₹440.00 to ₹735.00. Based on fundamentals like P/E (14.05), ROE (4.55%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Lincoln Pharmaceuticals Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹734.15. 2) Fundamental Deterioration - Declining ROE (currently 4.55%), increasing debt (D/E: 0.00), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Lincoln Pharmaceuticals Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.29%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Related
Explore peers, sector trends and screeners related to this stock.
Menu